<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216732</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0769</org_study_id>
    <secondary_id>NCI-2019-07526</secondary_id>
    <secondary_id>2019-0769</secondary_id>
    <nct_id>NCT04216732</nct_id>
  </id_info>
  <brief_title>Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management</brief_title>
  <official_title>Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study utilizes a multi-institutional registry to describe the natural history of&#xD;
      medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph&#xD;
      nodes, or distant parts of the body (advanced) in understanding disease management. The goal&#xD;
      of this study is to learn about how medullary thyroid cancer develops and progresses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the natural history of medullary thyroid cancer (MTC) using a comprehensive&#xD;
      battery of demographic, clinical, pathologic, and genotypic variables collected in our&#xD;
      existing multi-institutional patient registry.&#xD;
&#xD;
      Ia. To describe the demographic, clinical, pathologic, and genotypic variables associated&#xD;
      with each phase of disease.&#xD;
&#xD;
      Ib. To identify those variables which are predictors of progression to the most advanced&#xD;
      phases of disease that require small molecule therapy, including commercially approved and&#xD;
      experimental agents.&#xD;
&#xD;
      II. To characterize patients' experience with the different phases of MTC through a&#xD;
      systematic evaluation of patient-reported outcomes (PROs).&#xD;
&#xD;
      IIa. To describe clinical, psychosocial, economic, and physical well-being variables and the&#xD;
      subsequent impact on quality of life associated with each phase of disease.&#xD;
&#xD;
      IIb. To evaluate longitudinal changes in clinical, psychosocial, economic, and physical&#xD;
      well-being variables between and within all phases of MTC, and the subsequent impact they&#xD;
      have on quality of life.&#xD;
&#xD;
      III. To evaluate the association of selected biometric and patient-reported outcomes on&#xD;
      adherence, change, and discontinuation of approved targeted therapies and drugs being tested&#xD;
      within clinical trial.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      AIM I &amp; II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about&#xD;
      health and how finances and quality of life effect experience with disease.&#xD;
&#xD;
      AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure&#xD;
      measurements every day for up to 12 weeks.&#xD;
&#xD;
      The questionnaire data gets paired with the collected medical record history that is&#xD;
      maintained in the Registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history of medullary thyroid cancer (MTC)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will describe the natural history of MTC using comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in existing multi-institutional patient registry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients' experience with the different phases of MTC</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of selected biometric and patient-reported outcomes</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2030</enrollment>
  <condition>Advanced Thyroid Gland Medullary Carcinoma</condition>
  <condition>Stage III Thyroid Gland Medullary Carcinoma AJCC v8</condition>
  <condition>Stage IV Thyroid Gland Medullary Carcinoma AJCC v8</condition>
  <condition>Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8</condition>
  <condition>Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8</condition>
  <condition>Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Observational (questionnaire, blood pressure)</arm_group_label>
    <description>AIM I &amp; II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.&#xD;
AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Pressure Measurement</intervention_name>
    <description>Undergo blood pressure measurement</description>
    <arm_group_label>Observational (questionnaire, blood pressure)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (questionnaire, blood pressure)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with MTC including advanced phase MTC determined by clinical team&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aims 1 and 2: A diagnosis of MTC&#xD;
&#xD;
          -  Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients&#xD;
             of all disease phases will be eligible for enrollment&#xD;
&#xD;
          -  Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team&#xD;
&#xD;
          -  Aim 3: A current registrant in the MTCR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth G Grubbs</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth G Grubbs</last_name>
    <phone>713-792-6940</phone>
    <email>eggrubbs@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie A. Sosa</last_name>
      <phone>415-476-1236</phone>
    </contact>
    <investigator>
      <last_name>Julie A. Sosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth G. Grubbs</last_name>
      <phone>713-792-6940</phone>
      <email>eggrubbs@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth G. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>http://www.mdanderson.org</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Medullary</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

